Xerafy Revenue and Competitors
Estimated Revenue & Valuation
- Xerafy's estimated annual revenue is currently $17.1M per year.
- Xerafy's estimated revenue per employee is $247,500
Employee Data
- Xerafy has 69 Employees.
- Xerafy grew their employee count by 3% last year.
Xerafy's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Channel Sales - Americas | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Director, Corporate Finance & HR | Reveal Email/Phone |
4 | Sr. Sales and Solutions Manager | Reveal Email/Phone |
5 | Business Development Director | Reveal Email/Phone |
6 | Account Manager EMEA | Reveal Email/Phone |
Xerafy Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $17.1M | 69 | 3% | N/A | N/A |
What Is Xerafy?
Xerafy designs and manufactures the world's toughest RFID tags to power Industrial IoT applications for Aerospace, Oil & Gas, Manufacturing, Utilities and Healthcare. Our technology has been distinguished by EY, Frost & Sullivan, AIconics and Red Herring. Headquartered in Singapore, Xerafy operates in the Americas, EMEA and Asia Pacific regions.
keywords:N/A
N/A
Total Funding
69
Number of Employees
$17.1M
Revenue (est)
3%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Xerafy News
Becton Dickinson, Censis Technologies, Haldor, Getinge, Stanley Healthcare, SpaTrack Medical, TGX Medical Systems, Key Surgical, Xerafy.
... Inc., Key Surgical, Inc., Mobile Aspects, Stanley Healthcare, Tgx Medical Systems, Vizbee Rfid Solutions Ltd., Xerafy,. Market Scenario:.
Other promising players operating in the market are Syrma Technology, Xerafy, Getinge AB, B. Braun Melsungen AG.
Other Companies in Singapore
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $14.1M | 69 | N/A | N/A |
#2 | $12.5M | 69 | N/A | N/A |
#3 | $8.1M | 69 | 10% | N/A |
#4 | $10.1M | 70 | N/A | N/A |
#5 | $13.2M | 70 | N/A | N/A |